FibroScan used in street-based outreach for drug users is useful for hepatitis C virus screening and management: A prospective study

Journal of Viral Hepatitis

Volumn 16, Issue 2, 2009, Pages 121-131

  Foucher, J ^a   Reiller, B ^b   Jullien, V ^b   Leal F ^c   Di Cesare, E S ^b   Merrouche, W ^a   Delile, J M ^b   De Ledinghen V ^a,d  

^a HAUT LÉVÊQUE HOSPITAL   (France)

^b CEID   (France)

^c République Démocratique du Congo   (France)

^d INSERM   (France)

Author keywords

Cirrhosis; FibroScan; Fibrosis; Hepatitis C; Injection drug users; Transient elastography

Indexed keywords

COCAINE; DIAMORPHINE; VIRUS RNA;

ADULT; ALCOHOL ABUSE; ARTICLE; COMMUNITY PROGRAM; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DRUG ABUSE; ELASTOGRAPHY; FEMALE; HEALTH PROGRAM; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMAGE ANALYSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCREENING TEST;

ADULT; DRUG USERS; ELASTICITY IMAGING TECHNIQUES; FEMALE; HEALTH SERVICES RESEARCH; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; MALE; MASS SCREENING; PATIENT ACCEPTANCE OF HEALTH CARE; PROSPECTIVE STUDIES; QUESTIONNAIRES; RNA, VIRAL; SUBSTANCE-RELATED DISORDERS;

EID: 59149104257     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2008.01050.x     Document Type: Article

References (42)

1. Emmanuelli J, Desenclos JC. Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003. Addiction 2005 100 : 1690 1700.
2. Van Ameijden EJ, Langendam MW, Notenboom J, Coutinho RA. Continuing injecting risk behaviour: results from the Amsterdam Cohort Study of drug users. Addiction 1999 94 : 1051 1061.
3. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996 86 : 655 661.
4. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 2001 91 : 42 46.
5. Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999 341 : 556 562.
6. Rai R, Wilson LE, Astemborski J et al. Severity and correlates of liver disease in hepatitis C virus-infected injection drug users. Hepatology 2002 35 : 1247 1255.
7. Hadziyannis SJ, Sette Jr. H, Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 : 346 355.
8. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 982.
9. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 965.
10. Edlin BR, Seal KH, Lorvick J et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 2001 345 : 211 215.
11. Stephenson J. Former addicts face barriers to treatment for HCV. JAMA 2001 285 : 1003 1005.
12. Regev A, Berho M, Jeffers LJ et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002 97 : 2614 2618.
13. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003 38 : 1449 1457.
14. Cadranel J, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000 32 : 477 481.
15. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001 344 : 495 500.
16. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001 357 : 1069 1075.
17. Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003 38 : 518 526.
18. Forns X, Ampurdanes S, Llovet JM et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002 36 : 986 992.
19. Sterling RK, Lissen E, Clumeck N et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006 43 : 1317 1325.
20. Adams LA, Bulsara M, Rossi E et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005 51 : 1867 1873.
21. Castera L, Vergniol J, Foucher J et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005 128 : 343 350.
22. de Ledinghen V, Douvin C, Kettaneh A et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006 41 : 175 179.
23. Foucher J, Chanteloup E, Vergniol J et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006 55 : 403 408.
24. Ziol M, Handra-Luca A, Kettaneh A et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005 41 : 48 54.
25. Laharie D, Zerbib F, Adhoute X et al. Diagnosis of liver fibrosis by transient elastography (FibroScan) and non-invasive methods in Crohn's disease patients treated with methotrexate. Aliment Pharmacol Ther 2006 23 : 1621 1628.
26. Corpechot C, El Naggar A, Poujol-Robert A et al. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 2006 43 : 1118 1124.
27. Fontaine H, Petitprez K, Roudot-Thoraval F, Trinchet JC. Guidelines for the diagnosis of uncomplicated cirrhosis. Gastroenterol Clin Biol 2007 31 : 504 509.
28. Sandrin L, Fourquet B, Hasquenoph JM et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003 29 : 1705 1713.
29. van de Laar TJ, Langendam MW, Bruisten SM et al. Changes in risk behavior and dynamics of hepatitis C virus infections among young drug users in Amsterdam, the Netherlands. J Med Virol 2005 77 : 509 518.
30. Miller CL, Johnston C, Spittal PM et al. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology 2002 36 : 737 742.
31. Judd A, Hickman M, Jones S et al. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ 2005 330 : 24 25.
32. Fuller CM, Ompad DC, Galea S, Wu Y, Koblin B, Vlahov D. Hepatitis C incidence - a comparison between injection and noninjection drug users in New York City. J Urban Health 2004 81 : 20 24.
33. Murray JM, Law MG, Gao Z, Kaldor JM. The impact of behavioural changes on the prevalence of human immunodeficiency virus and hepatitis C among injecting drug users. Int J Epidemiol 2003 32 : 708 714.
34. Tompkins CN, Wright NM, Jones L. Impact of a positive hepatitis C diagnosis on homeless injecting drug users: a qualitative study. Br J Gen Pract 2005 55 : 263 268.
35. Micallef JM, Macdonald V, Jauncey M et al. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J Viral Hepat 2007 14 : 413 418.
36. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999 29 : 908 914.
37. Fischer B, Haydon E, Rehm J, Krajden M, Reimer J. Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach - the case study of Canada. J Urban Health 2004 81 : 428 447.
38. Wilson LE, Torbenson M, Astemborski J et al. Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology 2006 43 : 788 795.
39. Latkin CA, Vlahov D. Socially desirable response tendency as a correlate of accuracy of self-reported HIV serostatus for HIV seropositive injection drug users. Addiction 1998 93 : 1191 1197.
40. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001 34 : 188 193.
41. Jeffrey GP, MacQuillan G, Chua F et al. Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants. Hepatology 2007 45 : 111 117.
42. Sylvestre DL. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002 67 : 117 123.